This is the authors' abstract. We don't add key points for this paper.
Several clinical trials have demonstrated that anti-IL-5(R) biologics were able to improve lung function, asthma control and chronic oral corticosteroid exposure and reduce exacerbations among eosinophilic asthmatic patients. However, a certain variability in clinical responses to anti-IL-5(R) biologics was brought to light. Our study aimed at evaluating the role of baseline sputum eosinophils in identifying super-responders to mepolizumab and benralizumab. Our study reinforces the importance to examine sputum eosinophils in patients suffering from severe asthma before starting a biologic as it is associated with the intensity of response to mepolizumab and benralizumab.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gerday et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: